Caplin Point Laboratories downgraded to 'Hold' rating by MarketsMOJO

Caplin Point Laboratories, a midcap pharmaceutical company, has recently been downgraded to a 'Hold' rating by MarketsMOJO. This decision was based on various factors, including the company's high management efficiency with a ROE of 20.61% and low Debt to Equity ratio of 0 times. Additionally, the company has consistently declared positive results for the last 8 quarters, with its highest net sales and PBDIT in the last quarter at Rs 458.96 cr and Rs 151.81 cr respectively. Technically, the stock is currently in a mildly bullish range, with multiple factors such as MACD, Bollinger Band, and KST indicating a bullish trend. The majority shareholders of the company are its promoters, which can be seen as a positive sign for investors. In terms of performance, Caplin Point Laboratories has outperformed the BSE 500 index in the long term as well as the near term. In the last 1 year, the stock has generated a return of 91.76%, while in the last 3 years and 3 months, it has outperformed the index. However, the company has shown poor long term growth, with its operating profit growing at an annual rate of only 18.68% over the last 5 years. The stock is currently trading at a premium compared to its historical valuations, with a price to book value of 6.6 and a ROE of 19.7. This indicates that the stock may be overvalued and investors should be cautious. Additionally, while the stock has generated high returns in the past year, its profits have only risen by 21%, resulting in a PEG ratio of 1.5. Overall, while Caplin Point Laboratories has shown strong performance in the past, the current valuation and growth rate may not be sustainable in the long term. Investors are advised to hold their positions and monitor the company's performance closely.